RxDoctor Payments Data

Cassandra Terfehr, APRN

Nurse Practitioner · Cheyenne, WYNPI 1851818504

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,145in general payments, 2019–2025

Across 107 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$256
  • Lundbeck LLC$230
  • Novo Nordisk$197
  • AstraZeneca$152
  • Lilly USA, LLC$140
  • GSK$116
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,145100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,145 in reported general payments places this provider in the 90th percentile of 150 nurse practitioner providers in Wyoming.

See all nurse practitioner providers in Wyoming

Medicare billing

Part B allowed, 2024
$29,451
Medicare patients
96
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$13,789
TrulicityDulaglutide11$9,993
Advair DiskusFluticasone Propion/Salmeterol12$2,370
Albuterol Sulfate HfaAlbuterol Sulfate26$1,095
Omeprazole47$793
Bupropion XlBupropion Hcl28$740
Levothyroxine Sodium76$562
Atorvastatin Calcium70$505
Ropinirole Hcl12$448
Duloxetine Hcl12$430
Gabapentin34$402
Escitalopram Oxalate16$400
Hydroxyzine Hcl19$378
Losartan Potassium28$375
Metoprolol Succinate17$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$197$13,78914 claims
Lilly USA, LLCTrulicity$140$9,99311 claims
AbbVieSynthroid$86$11514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 150 nurse practitioner providers in Wyoming.

Other nurse practitioner in Cheyenne

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →